Calithera Biosciences, Inc. (CALA) financial statements (2020 and earlier)

Company profile

Business Address 343 OYSTER POINT BLVD #200
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:22511645272102
Cash and cash equivalents225148116102
Short-term investments  1154164 
Other undisclosed cash, cash equivalents, and short-term investments   02 
Receivables221   
Other undisclosed current assets113873212
Total current assets:1371401685472104
Noncurrent Assets
Property, plant and equipment112111
Long-term investments and receivables  22 2 
Long-term investments  22 2 
Restricted cash and investments000000
Other noncurrent assets01000 
Other undisclosed noncurrent assets8     
Total noncurrent assets:10225131
TOTAL ASSETS:1461431925576105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities71510446
Accounts payable111011
Accrued liabilities1149433
Employee-related liabilities4    1
Deferred revenue and credits29   
Other undisclosed current liabilities12    (1)
Total current liabilities:191539444
Noncurrent Liabilities
Liabilities, other than long-term debt 13000
Deferred revenue and credits3000
Deferred rent credit 1
Other liabilities     0
Other undisclosed noncurrent liabilities7     
Total noncurrent liabilities:713000
Total liabilities:261642544
Stockholders' equity
Stockholders' equity attributable to parent1211271505072100
Common stock000000
Additional paid in capital385323301172156152
Accumulated other comprehensive income (loss)0(0)(0)(0)(0) 
Accumulated deficit(264)(196)(150)(123)(84)(52)
Total stockholders' equity:1211271505072100
TOTAL LIABILITIES AND EQUITY:1461431925576105

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net26   
Gross profit: 2226   
Operating expenses(91)(80)(56)(38)(33)(22)
Operating loss:(91)(57)(30)(38)(33)(22)
Nonoperating income (expense)
(Investment Income, Nonoperating)
00(0)   
Other undisclosed income from continuing operations before equity method investments, income taxes222   
Loss before gain (loss) on sale of properties:(88)(55)(28)(38)(33)(22)
Other undisclosed net loss(1)     
Net loss:(89)(55)(28)(38)(33)(22)
Other undisclosed net income attributable to parent2  000
Net loss available to common stockholders, diluted:(88)(55)(28)(38)(33)(22)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(89)(55)(28)(38)(33)(22)
Comprehensive loss:(89)(55)(28)(38)(33)(22)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent20(0)00 
Comprehensive loss, net of tax, attributable to parent:(87)(54)(28)(38)(33)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: